Skip to main content
. 2020 Oct 15;2020:4850328. doi: 10.1155/2020/4850328

Figure 6.

Figure 6

Pinocembrin protects cardiomyocytes from simulated I/R injury via enhancing glycolysis. (a–d) Treatment with PFKFB3 inhibitor, 3PO, results in a decline of glycolysis and glycolytic capacity in mouse and rat cardiomyocytes. n = 3/treatment in all Seahorse assays, each in triplicate. (e, f) Effect of PFKFB3 inhibitor, 3PO, on mouse and rat cardiomyocyte cTnI release subsequent to H/R. n = 5 each. (g, h) Effect of PFKFB3 inhibitor, 3PO, on mouse and rat cardiomyocyte LDH release subsequent to H/R. n = 5 each. Data represent the mean ± SEM. ∗P < 0.05 versus H/R with the vehicle group. #P < 0.05 versus H/R with the PB group.